Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer.

Clinical lung cancer - 1 Jan 2015

Mak Raymond H, Hermann Gretchen, Lewis John H, Aerts Hugo J W L, Baldini Elizabeth H, Chen Aileen B, Colson Yolonda L, Hacker Fred H, Kozono David, Wee Jon O, Chen Yu-Hui, Catalano Paul J, Wong Kwok-Kin, Sher David J

Abstract excerpt

BACKGROUND: We analyzed outcomes after lung stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung-carcinoma (NSCLC) by histology and KRAS genotype. PATIENTS AND METHODS: We included 75 patients with 79 peripheral tumors treated with SBRT (18 Gy × 3 or 10 to 12 Gy × 5) at our institution from 2009 to 2012. Genotyping for KRAS mutations was performed in 10 patients. Outcomes were analyzed by the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Neoplasm Staging

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Predictive Value of Tests

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to Radiosurgery

Share to ras Proteins

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 25450872
DOI: 10.1016/j.cllc.2014.09.005
PMCID: PMC4427190

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer.PMID 25450872Read ↗

Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?Semantic proximity Read ↗

Intracranial Disease Control and Survival among Patients with KRAS-mutant Lung Adenocarcinoma and Brain Metastases Treated with Stereotactic Radiosurgery.Semantic proximity Read ↗

Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.Semantic proximity Read ↗

A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer.Semantic proximity Read ↗

Prognostic Impact and Recurrence Pattern of KRAS G12C Mutation in Surgically Resected Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.Semantic proximity Read ↗

Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non-squamous non-small cell lung cancer patients.Semantic proximity Read ↗

Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy.Semantic proximity Read ↗

Assessing Survival in Non-Small Cell Lung Cancer Brain Metastases After Stereotactic Radiosurgery: Before and After the Start of the Targetable Mutation EraSemantic proximity Read ↗

Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.Semantic proximity Read ↗

Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.Semantic proximity Read ↗

Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.